Stem Cell Research (Jun 2024)
Establishment of an induced pluripotent stem cell (iPSC) line (INNDSUi005-A) from a healthy female Chinese Han
- Wenzhu Liu,
- Yingxin Wang,
- Yitong Yang,
- Yu Wang,
- Yao Tang,
- Yichang Jiao,
- Didi Shan,
- Zexin Zhan,
- Rui Zhang,
- Dongdong Wang,
- Xiaohan Sun,
- Ping Sun,
- Xiulian Sun,
- Chuanzhu Yan,
- Fuchen Liu
Affiliations
- Wenzhu Liu
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Yingxin Wang
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Yitong Yang
- School of Nursing, Jining Medical University, Jining 272029, Shandong, People’s Republic of China
- Yu Wang
- Prenatal Diagnostic Center of Obstetrics and Gynecology Department, Qilu Hospital, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Yao Tang
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Yichang Jiao
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Didi Shan
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Zexin Zhan
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Rui Zhang
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Dongdong Wang
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Xiaohan Sun
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Ping Sun
- Prenatal Diagnostic Center of Obstetrics and Gynecology Department, Qilu Hospital, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Xiulian Sun
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Chuanzhu Yan
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China
- Fuchen Liu
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, People’s Republic of China; Corresponding author.
- Journal volume & issue
-
Vol. 77
p. 103386
Abstract
We obtained skin fibroblasts from a 34-year-old healthy woman and established a human induced pluripotent stem cell (hiPSC) line (INDSUi005-A) using a non-integrated reprogramming approach. The obtained cells have typical characteristics of embryonic stem cells, can express specific pluripotency markers and have the ability to differentiate into three germ layers in vitro. This iPSC cell line can be used as an in vitro model for studying disease mechanisms and developing novel therapies.